DK174686B1 - Antikonvulsive aminosyreforbindelsesholdige midler, anvendelse af disse forbindelser til fremstilling af antikonvulsive lægemidler samt forbindelserne selv - Google Patents

Antikonvulsive aminosyreforbindelsesholdige midler, anvendelse af disse forbindelser til fremstilling af antikonvulsive lægemidler samt forbindelserne selv Download PDF

Info

Publication number: DK174686B1
Authority: DK; Denmark
Prior art keywords: benzyl; acetamido; substituents; compound; electron
Prior art date: 1986-08-21

Application number

DK198705260A

Other languages

Danish (da)

English (en)

Other versions

DK526087D0 (da

DK526087A (da

Inventor

Harold L Kohn

Darrell Watson

Original Assignee

Res Corp Technologies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-21

Filing date

1987-10-07

Publication date

2003-09-08

1986-08-21 Priority claimed from AU61766/86A external-priority patent/AU595538C/en

1987-10-07 Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc

1987-10-07 Publication of DK526087D0 publication Critical patent/DK526087D0/da

1988-04-08 Publication of DK526087A publication Critical patent/DK526087A/da

2003-09-08 Application granted granted Critical

2003-09-08 Publication of DK174686B1 publication Critical patent/DK174686B1/da

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 63
239000001961 anticonvulsive agent Substances 0.000 title claims abstract description 18
238000002360 preparation method Methods 0.000 title claims abstract description 16
239000003795 chemical substances by application Substances 0.000 title claims description 19
230000002082 anti-convulsion Effects 0.000 title description 3
150000001413 amino acids Chemical class 0.000 title 1
230000001773 anti-convulsant effect Effects 0.000 claims abstract description 11
229960003965 antiepileptics Drugs 0.000 claims abstract description 8
239000003937 drug carrier Substances 0.000 claims abstract description 5
125000001424 substituent group Chemical group 0.000 claims description 28
229910052739 hydrogen Inorganic materials 0.000 claims description 20
125000000217 alkyl group Chemical group 0.000 claims description 15
-1 β-naphthyl Chemical group 0.000 claims description 15
125000003118 aryl group Chemical group 0.000 claims description 14
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
229910052757 nitrogen Inorganic materials 0.000 claims description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 7
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 7
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 5
ZXOUJKZTYIKUBQ-UHFFFAOYSA-N 2-acetamido-n-benzyl-2-thiophen-3-ylacetamide Chemical compound C1=CSC=C1C(NC(=O)C)C(=O)NCC1=CC=CC=C1 ZXOUJKZTYIKUBQ-UHFFFAOYSA-N 0.000 claims description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
125000003342 alkenyl group Chemical group 0.000 claims description 3
125000000304 alkynyl group Chemical group 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
239000000460 chlorine Substances 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims 5
150000002431 hydrogen Chemical class 0.000 claims 5
125000000623 heterocyclic group Chemical group 0.000 claims 3
YKOROOIYLWQAEC-UHFFFAOYSA-N 2-acetamido-n-benzyl-2-(1h-pyrrol-2-yl)acetamide Chemical compound C=1C=CNC=1C(NC(=O)C)C(=O)NCC1=CC=CC=C1 YKOROOIYLWQAEC-UHFFFAOYSA-N 0.000 claims 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
125000005842 heteroatom Chemical group 0.000 claims 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
125000003828 azulenyl group Chemical group 0.000 claims 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
125000001589 carboacyl group Chemical group 0.000 claims 1
150000003857 carboxamides Chemical class 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
229910052731 fluorine Inorganic materials 0.000 claims 1
239000011737 fluorine Substances 0.000 claims 1
125000002541 furyl group Chemical group 0.000 claims 1
150000002391 heterocyclic compounds Chemical class 0.000 claims 1
125000002883 imidazolyl group Chemical group 0.000 claims 1
125000001041 indolyl group Chemical group 0.000 claims 1
125000001786 isothiazolyl group Chemical group 0.000 claims 1
125000000842 isoxazolyl group Chemical group 0.000 claims 1
125000001624 naphthyl group Chemical group 0.000 claims 1
125000002971 oxazolyl group Chemical group 0.000 claims 1
229910052760 oxygen Inorganic materials 0.000 claims 1
239000001301 oxygen Substances 0.000 claims 1
125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 claims 1
229910052698 phosphorus Inorganic materials 0.000 claims 1
239000011574 phosphorus Substances 0.000 claims 1
125000004193 piperazinyl group Chemical group 0.000 claims 1
125000005936 piperidyl group Chemical group 0.000 claims 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
125000003373 pyrazinyl group Chemical group 0.000 claims 1
125000003226 pyrazolyl group Chemical group 0.000 claims 1
125000002098 pyridazinyl group Chemical group 0.000 claims 1
125000004076 pyridyl group Chemical group 0.000 claims 1
125000000714 pyrimidinyl group Chemical group 0.000 claims 1
125000001422 pyrrolinyl group Chemical group 0.000 claims 1
125000000168 pyrrolyl group Chemical group 0.000 claims 1
125000001453 quaternary ammonium group Chemical group 0.000 claims 1
125000005493 quinolyl group Chemical group 0.000 claims 1
150000003462 sulfoxides Chemical class 0.000 claims 1
239000011593 sulfur Substances 0.000 claims 1
125000003831 tetrazolyl group Chemical group 0.000 claims 1
125000000335 thiazolyl group Chemical group 0.000 claims 1
125000001544 thienyl group Chemical group 0.000 claims 1
150000003573 thiols Chemical class 0.000 claims 1
125000001425 triazolyl group Chemical group 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 29
206010015037 epilepsy Diseases 0.000 abstract description 8
239000003814 drug Substances 0.000 abstract description 7
239000004615 ingredient Substances 0.000 abstract description 6
208000015114 central nervous system disease Diseases 0.000 abstract description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
238000005481 NMR spectroscopy Methods 0.000 description 23
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
206010010904 Convulsion Diseases 0.000 description 14
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
229910052799 carbon Inorganic materials 0.000 description 13
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
238000000034 method Methods 0.000 description 12
239000000243 solution Substances 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
238000001819 mass spectrum Methods 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
239000002244 precipitate Substances 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000002329 infrared spectrum Methods 0.000 description 8
239000000047 product Substances 0.000 description 8
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 7
239000007787 solid Substances 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000002904 solvent Substances 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 5
238000007792 addition Methods 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 5
239000002775 capsule Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
231100000816 toxic dose Toxicity 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000002253 acid Substances 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
229940079593 drug Drugs 0.000 description 4
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
238000003818 flash chromatography Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
229960005152 pentetrazol Drugs 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
229910015900 BF3 Inorganic materials 0.000 description 3
101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000002841 Lewis acid Substances 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000011149 active material Substances 0.000 description 3
150000008064 anhydrides Chemical class 0.000 description 3
229940125681 anticonvulsant agent Drugs 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
239000000470 constituent Substances 0.000 description 3
238000000921 elemental analysis Methods 0.000 description 3
239000012433 hydrogen halide Substances 0.000 description 3
229910000039 hydrogen halide Inorganic materials 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
150000007517 lewis acids Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
229960002036 phenytoin Drugs 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
SFUPOCRPODJHEI-UHFFFAOYSA-N 2-acetamido-n-benzyl-4-methylsulfanylbutanamide Chemical compound CSCCC(NC(C)=O)C(=O)NCC1=CC=CC=C1 SFUPOCRPODJHEI-UHFFFAOYSA-N 0.000 description 2
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
241000167854 Bourreria succulenta Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
208000003443 Unconsciousness Diseases 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
235000019693 cherries Nutrition 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000036461 convulsion Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
125000002576 diazepinyl group Chemical class N1N=C(C=CC=C1)* 0.000 description 2
239000002612 dispersion medium Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
125000001072 heteroaryl group Chemical group 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000007135 neurotoxicity Effects 0.000 description 2
231100000228 neurotoxicity Toxicity 0.000 description 2
229960003396 phenacemide Drugs 0.000 description 2
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
229960002695 phenobarbital Drugs 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
DRSFJLYEOMCWJG-UHFFFAOYSA-N 2-acetamido-n-benzyl-2-ethoxyacetamide Chemical compound CCOC(NC(C)=O)C(=O)NCC1=CC=CC=C1 DRSFJLYEOMCWJG-UHFFFAOYSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
206010003628 Atonic seizures Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
229910014033 C-OH Inorganic materials 0.000 description 1
101100219382 Caenorhabditis elegans cah-2 gene Proteins 0.000 description 1
101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010009346 Clonus Diseases 0.000 description 1
229920000114 Corrugated plastic Polymers 0.000 description 1
229910014570 C—OH Inorganic materials 0.000 description 1
241000233866 Fungi Species 0.000 description 1
101100295741 Gallus gallus COR4 gene Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000034308 Grand mal convulsion Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
208000002033 Myoclonus Diseases 0.000 description 1
XUYPXLNMDZIRQH-UHFFFAOYSA-N N-acetylmethionine Chemical compound CSCCC(C(O)=O)NC(C)=O XUYPXLNMDZIRQH-UHFFFAOYSA-N 0.000 description 1
VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 description 1
206010061334 Partial seizures Diseases 0.000 description 1
206010034759 Petit mal epilepsy Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
238000005644 Wolff-Kishner reduction reaction Methods 0.000 description 1
239000000370 acceptor Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
230000036626 alertness Effects 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
GRSTVVGJSKHCCS-UHFFFAOYSA-N bis(1h-imidazol-2-yl)methanone Chemical class N=1C=CNC=1C(=O)C1=NC=CN1 GRSTVVGJSKHCCS-UHFFFAOYSA-N 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000007958 cherry flavor Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003480 eluent Substances 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
SXKFFPJMOPJBAH-UHFFFAOYSA-N ethyl 2-acetamido-2-ethoxyacetate Chemical compound CCOC(NC(C)=O)C(=O)OCC SXKFFPJMOPJBAH-UHFFFAOYSA-N 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
125000006038 hexenyl group Chemical group 0.000 description 1
125000005980 hexynyl group Chemical group 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
150000001469 hydantoins Chemical class 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 1
229960000906 mephenytoin Drugs 0.000 description 1
FKNMSDVAGYOANC-UHFFFAOYSA-N methyl 2-acetamido-2-methoxyacetate Chemical compound CC(=O)NC(OC)C(=O)OC FKNMSDVAGYOANC-UHFFFAOYSA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
238000006396 nitration reaction Methods 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
238000006053 organic reaction Methods 0.000 description 1
150000001475 oxazolidinediones Chemical class 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
229960003274 paramethadione Drugs 0.000 description 1
230000001314 paroxysmal effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
125000005981 pentynyl group Chemical group 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000079 pharmacotherapeutic effect Effects 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
150000003333 secondary alcohols Chemical class 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
125000005490 tosylate group Chemical group 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
125000004954 trialkylamino group Chemical group 0.000 description 1
IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
229960004453 trimethadione Drugs 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Peptides Or Proteins (AREA)

DK198705260A 1986-08-21 1987-10-07 Antikonvulsive aminosyreforbindelsesholdige midler, anvendelse af disse forbindelser til fremstilling af antikonvulsive lægemidler samt forbindelserne selv DK174686B1 (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
AU61766/86A AU595538C (en)		1986-08-21	Amides of N-acylated amino acids as anticonvulsants
AU6176686		1986-08-21
US91625486A	1986-10-07	1986-10-07
US91625486		1986-10-07
US8052887A	1987-07-31	1987-07-31
US8052887		1987-07-31

Publications (3)

Publication Number	Publication Date
DK526087D0 DK526087D0 (da)	1987-10-07
DK526087A DK526087A (da)	1988-04-08
DK174686B1 true DK174686B1 (da)	2003-09-08

Family

ID=36926794

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198705260A DK174686B1 (da)	1986-08-21	1987-10-07	Antikonvulsive aminosyreforbindelsesholdige midler, anvendelse af disse forbindelser til fremstilling af antikonvulsive lægemidler samt forbindelserne selv

Country Status (11)

Country	Link
EP (1)	EP0263506B1 (fr)
JP (1)	JP2580196B2 (fr)
AT (1)	ATE92315T1 (fr)
CA (1)	CA1340904C (fr)
DE (1)	DE3786865T2 (fr)
DK (1)	DK174686B1 (fr)
ES (2)	ES2058085T3 (fr)
GR (1)	GR871549B (fr)
IE (1)	IE61437B1 (fr)
NZ (1)	NZ222045A (fr)
PT (1)	PT85869B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5654301A (en) *	1985-02-15	1997-08-05	Research Corporation Technologies, Inc.	Amino acid derivative anticonvulsant
US5378729A (en) *	1985-02-15	1995-01-03	Research Corporation Technologies, Inc.	Amino acid derivative anticonvulsant
CA2017217C (fr) *	1989-05-19	2002-02-19	Harold L. Kohn	Derives d'acides amines anticonvulsivant
US6028102A (en) *	1998-02-24	2000-02-22	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Anticonvulsant drugs and pharmaceutical compositions thereof
EP1541138A1 (fr) *	2003-12-05	2005-06-15	Schwarz Pharma Ag	Nouvelle utilisation de peptides pour le traitement de la status epilepticus et etats connexes
EP1604656A1 (fr)	2004-06-09	2005-12-14	Schwarz Pharma Ag	Utilisation nouvelle de peptides pour le traitement de la sclérose amytrophique latérale (ALS)
US7676933B2 (en)	2006-04-28	2010-03-16	Restaurant Technology, Inc.	Spatula and blade
US7900329B2 (en)	2006-04-28	2011-03-08	Restaurant Technology, Inc.	Spatula blade changing apparatus and method
JP5564570B2 (ja) *	2009-09-25	2014-07-30	カディラ・ヘルスケア・リミテッド	ラコサミドおよびその中間体の調製方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4372974A (en) *	1980-06-25	1983-02-08	New York University	Anticonvulsive compositions and method of treating convulsive disorders
FR2489319A1 (fr) *	1980-08-27	1982-03-05	Clin Midy	Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant
BE885303A (fr) *	1980-09-19	1981-03-19	Continental Pharma	Glycinamides
CA1340902C (fr) *	1985-02-15	2000-02-22	Harold L. Kohn	Compose anticonvulsif a base d'un derive d'acide amine

1987
- 1987-10-05 NZ NZ222045A patent/NZ222045A/xx unknown
- 1987-10-06 PT PT85869A patent/PT85869B/pt unknown
- 1987-10-07 CA CA000548825A patent/CA1340904C/fr not_active Expired - Lifetime
- 1987-10-07 DK DK198705260A patent/DK174686B1/da not_active IP Right Cessation
- 1987-10-07 EP EP87114623A patent/EP0263506B1/fr not_active Expired - Lifetime
- 1987-10-07 GR GR871549A patent/GR871549B/el unknown
- 1987-10-07 DE DE87114623T patent/DE3786865T2/de not_active Expired - Lifetime
- 1987-10-07 AT AT87114623T patent/ATE92315T1/de not_active IP Right Cessation
- 1987-10-07 IE IE267287A patent/IE61437B1/en not_active IP Right Cessation
- 1987-10-07 ES ES87114623T patent/ES2058085T3/es not_active Expired - Lifetime
- 1987-10-07 ES ES8703013A patent/ES2005042A6/es not_active Expired
- 1987-10-07 JP JP62256140A patent/JP2580196B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NZ222045A (en)	1989-10-27
JPS63132832A (ja)	1988-06-04
DK526087D0 (da)	1987-10-07
ES2005042A6 (es)	1989-02-16
EP0263506A3 (en)	1990-03-28
AU595538B2 (en)	1990-04-05
PT85869A (en)	1987-11-01
DE3786865T2 (de)	1993-12-09
PT85869B (pt)	1990-07-31
EP0263506B1 (fr)	1993-08-04
CA1340904C (fr)	2000-02-22
IE872672L (en)	1988-04-07
ES2058085T3 (es)	1994-11-01
JP2580196B2 (ja)	1997-02-12
GR871549B (en)	1988-02-12
DE3786865D1 (de)	1993-09-09
DK526087A (da)	1988-04-08
EP0263506A2 (fr)	1988-04-13
IE61437B1 (en)	1994-11-02
AU6176686A (en)	1988-02-25
ATE92315T1 (de)	1993-08-15

Legal Events

Date	Code	Title	Description
2007-10-22	PUP	Patent expired

Publication	Publication Date	Title
US6048899A (en)	2000-04-11	Anticonvulsant enantiomeric amino acid derivatives
EP0281459B1 (fr)	1995-04-26	Enantiomère dextrogyre de l'alpha-(tétrahydro-4,5,6,7 thiéno (3,2-c)pyridyl-5) (chloro-2 phényl)-acétate de méthyle, son procédé de préparation et les compositions pharmaceutiques le renfermant
CA2110693C (fr)	2003-05-20	Derive d'acide amine anticonvulsif
CA1265517A (fr)	1990-02-06	DERIVES DE L'ACIDE .alpha.-[OXO-2 HEXAHYDRO-2,4,5,6,7, 7A THIENO (3,2-C) PYRIDYL-5] PHENYL ACETIQUE, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION THERAPEUTIQUE
US5563136A (en)	1996-10-08	3-Ureidobenzodiazepinones useful as antagonists of CCK or of gastrin
EP0194464B1 (fr)	1991-04-03	Dérivés d'acides aminés et leur utilisation pour la préparation d'un anticonvulsif
DE69729392T2 (de)	2005-06-02	Krampfhemmende enantiomere Aminosäurederivate
MC1441A1 (fr)	1982-12-06	Imidazodiazepines
EP0431991B1 (fr)	1994-01-12	Nouveaux dérivés de benzonaphtyridine-1,8 leur préparation et les compositions qui les contiennent
FR2659329A1 (fr)	1991-09-13	Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant.
EP0263506B1 (fr)	1993-08-04	Compositions anticonvulsantes contenant des dérivés d'acides aminés et utilisation desdits dérivés d'acides aminés
EP0400440B1 (fr)	2002-03-13	Dérivés anticonvulsifs d'aminoacides
CH620912A5 (fr)	1980-12-31
MC1279A1 (fr)	1980-05-23	Dérivés de la benzodiazépine
SU1685264A3 (ru)	1991-10-15	Способ получени производных пиррола
RU2067579C1 (ru)	1996-10-10	3-(2'-нафтоилметилен)-пиперазинон-2 и 1-n-фенил-3-фенацилиденпиперазинон-2, проявляющие противовоспалительную активность
SU1321375A3 (ru)	1987-06-30	Способ получени производных дигидробензопирана или дигидробензотиопирана или их фармацевтически приемлемых солей
CZ298140B6 (cs)	2007-07-04	Zpusob prípravy cyklických amidu
US4402964A (en)	1983-09-06	N-Aryl-N'-(3-methyl or ethyl-4-oxothiazolidinylidene)ureas useful for the treatment of epilepsy
AU609062B2 (en)	1991-04-26	Amino acid derivative anticonvulsant
Tita et al.	1987	Synthesis of novel 4‐amino‐1, 4‐benzodiazepine‐2, 5‐diones for anticonvulsant testing
MC1730A1 (fr)	1986-12-15	Derives de l'imidazodiazepine
FR2497202A1 (fr)	1982-07-02	Nouveaux derives de tetrahydro-1,2,4-oxadiazin-5-one, leur preparation et compositions pharmaceutiques les contenant
FR2730489A1 (fr)	1996-08-14	Derives de 1-(2-(vinyl-substitues))-5h-2,3-benzodiazepine
IE84051B1 (en)		Amino acid derivative anticonvulsant